Dicerna Pharmaceuticals

279 articles with Dicerna Pharmaceuticals

• Dicerna™ Announces the Presentation of Updated Data Demonstrating Utility of its Lead Compound DCR-PHXC in Treating Primary Hyperoxaluria Type 1 (PH1) and Type 2 (PH2)

  3/29/2019

  PHYOX™1 Investigators Reported Potent, Durable Response in Phase 1 Study in Patients with PH1 and PH2 at German Society of Pediatric Nephrology 50th Annual Meeting

• Dicerna™ Reports Fourth Quarter and Year Ended December 31, 2018 Financial Results and Provides Corporate Update

  3/11/2019

  2018 was a Milestone Year for Dicerna Across a Variety of Fronts, Including Data Readouts for Primary Hyperoxaluria, Business Development Collaborations and a Successful Follow-On Offering

• Dicerna to Report Fourth Quarter and Year End 2018 Financial Results and Host Conference Call on March 11, 2019

  3/4/2019

  Dicerna Pharmaceuticals, Inc. announced that the Company will release its fourth quarter and year end 2018 financial results after market close on Monday, March 11, 2019.

• Dicerna Pharmaceuticals, Inc. Reports Inducement Grant Under NASDAQ Listing Rule 5635(c)(4) - March 1, 2019

  3/1/2019

  Dicerna Pharmaceuticals, Inc. announced that the Compensation Committee of the Company's Board of Directors approved the grant of inducement stock options to purchase a total of 238,000 shares of common stock to be distributed among six new employees, with a grant date of March 1, 2019.

• Dicerna Pharmaceuticals to Present at Upcoming Investor Conferences

  2/22/2019

  Dicerna Pharmaceuticals, Inc., a leading developer of investigational ribonucleic acid interference therapeutics, announced that Douglas M. Fambrough, Ph.D., president and chief executive officer, will present a corporate overview at the following investor conferences in March

• Dicerna Bolsters Leadership Team to Support Continued Growth

  2/21/2019

  Dicerna Pharmaceuticals, Inc., a leading developer of investigational ribonucleic acid interference (RNAi) therapeutics, today announced the addition of three industry veterans to the Company’s management team

• ADDING MULTIMEDIA Dicerna Bolsters Leadership Team to Support Continued Growth

  2/21/2019

  — Regina DeTore Paglia Joins Company as Senior Vice President of Human Resources — Rebecca Peterson Hired as Head of Corporate Communications — Hardean E. Achneck, M.D., Joins as Vice President, Head of Medical Development

• Dicerna Pharmaceuticals, Inc. Reports Inducement Grant Under NASDAQ Listing Rule 5635(c)(4)

  2/1/2019

  Dicerna Pharmaceuticals, Inc. announced that the Compensation Committee of the Company's Board of Directors approved the grant of inducement stock options to purchase a total of 419,000 shares of common stock to be distributed among 14 new employees with a grant date of February 1, 2019.

• Dicerna Announces Dosing of First Volunteer in Phase 1 Clinical Trial of DCR-HBVS Designed for the Treatment of Chronic Hepatitis B Virus

  1/28/2019

  Clinical Proof-of-Concept Data Expected in Second Half of 2019

• 

  BioSpace Movers and Shakers: Jan. 25

  1/25/2019

  Movers and Shakers is BioSpace's weekly roundup of leadership appointments and changes within the biopharma world. Included this week are Genentech, Editas, Sage, Sangamo, and more.

• Dicerna Evolves Its Board of Directors to Support Continued Growth

  1/24/2019

  J. Kevin Buchi Assumes Chairmanship Role and Industry Experts Marc Kozin and Anna Protopapas Join Dicerna Board

• Dicerna Pharmaceuticals, Inc. Reports Inducement Grant Under NASDAQ Listing Rule 5635(c)(4) on January 2, 2019

  1/8/2019

  Dicerna Pharmaceuticals, Inc. today announced that on January 2, 2019, the Compensation Committee of the Company's Board of Directors approved the grant of inducement stock options to purchase a total of 182,000 shares of common stock to be distributed among nine new employees, with a grant date of January 2, 2019 (the "Inducement Grant").

• Boehringer Ingelheim Exercises Option on Second Hepatic Disease Target from Research Collaboration with Dicerna

  1/4/2019

  Boehringer Ingelheim and Dicerna Pharmaceuticals announced that Boehringer Ingelheim has exercised an option to receive exclusive rights to a second hepatic disease target emerging from its research collaboration and license agreement with Dicerna.

• Dicerna to Join NASDAQ Biotechnology Index

  12/20/2018

  Dicerna Pharmaceuticals, Inc. today announced that the Company will be added to the NASDAQ Biotechnology Index (Nasdaq:NBI) as part of the annual re-ranking, which will become effective prior to market open on Monday, December 24, 2018.

• Dicerna Announces Closing of Global Licensing and Research Collaboration with Eli Lilly and Company

  12/19/2018

  The companies entered into a global licensing and research collaboration focused on the discovery, development and commercialization of potential new medicines in the areas of cardio-metabolic disease, neurodegeneration and pain.

• Dicerna to Participate in Citi’s 2018 Global Healthcare Conference

  11/29/2018

  Douglas M. Fambrough, Ph.D., president and chief executive officer, will host one-on-one investor meetings at Citi’s 2018 Global Healthcare Conference at the Lotte New York Palace Hotel in New York on Thursday, December 6, 2018.

• Dicerna to Highlight Lead GalXC™ Pipeline Programs, Collaborations, and Advances to GalXC Technology Platform at R&D Day 2018

  11/9/2018

  Dicerna Pharmaceuticals, Inc. will host an R&D Day today in New York City to discuss its pipeline of GalXC™-based RNAi therapeutic candidates.

• Dicerna to Participate in Upcoming November 2018 Investor Conferences

  11/6/2018

  Dicerna Pharmaceuticals, Inc. today announced that Douglas M. Fambrough, Ph.D., president and chief executive officer, will participate in three investor conferences in November.

• Dicerna Reports Third Quarter 2018 Financial and Operating Results and Provides Corporate Update

  11/5/2018

  Demonstrated Clinical POC for DCR-PHXC in Primary Hyperoxaluria and On Track to Initiate Registration Trial in Q1 2019

• Dicerna to Report Third Quarter 2018 Financial Results and Host Conference Call on November 5, 2018

  10/30/2018

  Dicerna Pharmaceuticals, Inc. today announced that the Company will release its third quarter 2018 financial results after market close on Monday, November 5, 2018.